Unveiling the Power of Early Type 1 Diabetes Detection: A Conversation with Shara Bialo, MD
In a recent interview with Pharmacy Times, Shara Bialo, MD, sheds light on the critical importance of early detection of Type 1 Diabetes (T1D) and the role of autoantibody screening in enhancing patient outcomes. As a senior medical director at Sanofi and a pediatric endocrinologist living with T1D, Bialo emphasizes the significance of this topic during American Diabetes Month.
The Importance of Early Detection
Bialo highlights the staggering number of people diagnosed with Type 1 Diabetes each year, approximately 64,000, with a surprising majority being adults. This dispels the common myth that T1D only affects children. She explains that early detection through autoantibody screening can prevent diabetic ketoacidosis (DKA), a life-threatening condition where the body struggles to use glucose and resorts to burning ketones for energy.
By catching T1D early, patients and their families can be educated and prepared for insulin therapy, avoiding the crisis state of DKA. This early intervention not only reduces the risk of DKA but also provides a precious gift of time, allowing patients and families to adapt to the diagnosis at their own pace.
Overcoming Barriers to Autoantibody Screening
Despite growing awareness, autoantibody screening is not yet standard practice. Bialo identifies several barriers that hinder its adoption among healthcare professionals (HCPs). These include clinician awareness of the three stages of T1D, the process of ordering and interpreting autoantibodies, and concerns about cost and reimbursement. Additionally, workflow constraints within clinical care and patient anxiety about asymptomatic conditions are factors that need addressing.
However, Bialo offers a glimmer of hope. Recent advancements in medical guidance, such as consensus on managing patients with autoantibody positivity, and recommendations from diabetes-specific societies like the American Diabetes Association, provide valuable resources for HCPs. These guidelines suggest screening individuals with a family history of T1D or autoimmune diseases, who are at a significantly higher risk.
The Role of Pharmacists in Early Detection
Pharmacists, according to Bialo, are invaluable partners in the fight against T1D. Due to their frequent interactions with patients and families, pharmacists can initiate and reinforce screening conversations. They can identify potential candidates based on family history, symptoms, and medications, providing education on the increased risk of T1D among family members with a history of the disease.
By empowering patients and families to take the next step in screening, pharmacists contribute to a more informed and supported patient population. Repetition of screening messages from various healthcare professionals further reinforces the importance of early detection, ensuring a cohesive and comprehensive approach to patient care.
Stay tuned for more insights on drug updates, treatment guidelines, and pharmacy practice trends by subscribing to Pharmacy Times for weekly clinical updates.
